Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Table 2 Follow-up outcomes of patients after inverse probability treatment weighting

Outcome	ARNI	SGLT2i	aHR or aSHR of ARNI (95% CI)^c	P
CV outcome
Composite of HHF and CV death^a	258 (39.9)	255 (30.4)	1.14 (0.99–1.31)	0.069
Hospitalization for heart failure^b	244 (37.7)	228 (27.1)	1.22 (1.06–1.41)	0.006
Cardiovascular death^a	37 (5.7)	47 (5.6)	0.74 (0.52–1.06)	0.101
All-cause death^a	88 (13.6)	100 (11.9)	0.98 (0.77–1.24)	0.837
Myocardial infarction^b	22 (3.4)	24 (2.9)	1.40 (0.88–2.22)	0.159
Ischemic stroke^b	11 (1.7)	14 (1.7)	0.99 (0.53–1.86)	0.972
Renal outcome
Serum creatinine doubling^b	85 (13.1)	78 (9.3)	1.35 (1.05–1.75)	0.022
eGFR decline > 50%^b	161 (24.9)	168 (20.0)	1.21 (1.02–1.45)	0.034
End-stage renal disease^b	20 (3.1)	13 (1.5)	2.91 (1.62–5.23)	< 0.001
Potassium (K) > 6 mEq/L^b	32 (4.9)	21 (2.5)	1.53 (0.99–2.35)	0.055

Data are presented as frequencies (percentages)
aHR adjusted hazard ratio, ARNI angiotensin receptor–neprilysin inhibitor, aSHR adjusted subdistribution hazard ratio, CI confidence interval, CV cardiovascular, eGFR estimated glomerular filtration rate, HHF hospitalization for heart failure, SGLT2i sodium–glucose cotransporter 2 inhibitors
^aCox proportional hazard model with aHR
^bFine and Gray subdistribution hazard model with aSHR
^cAdjusted for baseline LVESD, glycated hemoglobin, use of metformin and sulfonylurea

ISSN: 1758-5996